Antisense raises $5 million
Friday, 22 August, 2003
Drug discovery biotech Antisense Therapeutics (ASX:ANP) has added AUD$5 million to its coffers with the placement of 38.5 million new shares to the institutional and specialist investor market.
The placement, which was managed by ABN Amro Morgans, attracted some new institutional investors as well as existing shareholders, and was oversubscribed at close. Circadian Technologies (ASX:CIR) subscribed to approximately $1 million worth of the raising, subject to shareholder approval.
The cash will be channeled directly into further R&D into the company's multiple sclerosis therapeutic, ATL1102, and psoriasis treatment ATL1101, as well as for other drug discovery activities.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
